Press releases

Search Press releases

27 Dec 2023

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

4 Dec 2023

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

1 Dec 2023

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

23 Nov 2023

Transparency notification Wellington

16 Nov 2023

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

11 Nov 2023

Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels

Stay up-to-date on the latest news and information from UCB

instagram
facebook
twitter
youtube
linkedin
rss

Press releases

This section is intended for media and financial analysts

Search Press releases

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Transparency notification Wellington

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels

Choose a Country

Our Company

Disease Areas

Our Science

Our Products

Newsroom

Patients

Investors

HCP

Clinical Studies

This section is intended for media and financial analysts

Search Press releases

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Transparency notification Wellington

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels

Choose a Country

Our Company

Disease Areas

Our Science

UCB Worldwide

Our Products

Newsroom

Patients

Investors

HCP

Clinical Studies